CytomX Therapeutics, Inc. (CTMX) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth No data.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth No data.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth No data.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth No data.
41/80
2.6 / 5 stars
All 80 Win/Lose results and 40 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 3 wins, 5 losses, 4 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/2 |
LoseCTMX / S&P -20.21% / 15.20% |
LoseCTMX / S&P -87.03% / 15.00% |
No dataCTMX / S&P / 50.40% |
| 2026-Q11/2 |
WinCTMX / S&P 10.33% / -4.33% |
LoseCTMX / S&P -75.91% / 11.30% |
No dataCTMX / S&P / 27.70% |
| 2025-Q41/2 |
WinCTMX / S&P 33.54% / 2.65% |
LoseCTMX / S&P -44.82% / 9.00% |
No dataCTMX / S&P / 13.40% |
| 2025-Q31/2 |
WinCTMX / S&P 40.53% / 8.12% |
LoseCTMX / S&P -10.26% / 4.61% |
No dataCTMX / S&P / 13.45% |
| 2025-Q22/2 |
WinCTMX / S&P 256.92% / 10.94% |
WinCTMX / S&P 18.01% / 4.83% |
No dataCTMX / S&P / 10.63% |
| 2025-Q11/2 |
LoseCTMX / S&P -38.25% / -4.27% |
WinCTMX / S&P 23.81% / 4.98% |
No dataCTMX / S&P / 10.57% |
| 2024-Q41/2 |
LoseCTMX / S&P -12.71% / 2.41% |
WinCTMX / S&P 36.45% / 5.25% |
No dataCTMX / S&P / 6.15% |
| 2024-Q31/2 |
LoseCTMX / S&P -3.28% / 5.89% |
WinCTMX / S&P 33.66% / 5.89% |
No dataCTMX / S&P / 6.11% |
| 2024-Q21/2 |
LoseCTMX / S&P -44.04% / 4.28% |
WinCTMX / S&P 50.41% / 5.38% |
No dataCTMX / S&P / 5.12% |
| 2024-Q12/2 |
WinCTMX / S&P 40.65% / 10.56% |
WinCTMX / S&P 76.24% / 5.71% |
No dataCTMX / S&P / 5.59% |
| 2023-Q42/2 |
WinCTMX / S&P 20.16% / 11.69% |
WinCTMX / S&P 90.38% / 6.81% |
No dataCTMX / S&P / 7.78% |
| 2023-Q31/2 |
LoseCTMX / S&P -25.00% / -3.27% |
WinCTMX / S&P 361.96% / 7.52% |
No dataCTMX / S&P / -5.03% |
| 2023-Q22/2 |
WinCTMX / S&P 13.91% / 8.74% |
WinCTMX / S&P 195.01% / 9.50% |
No dataCTMX / S&P / -8.57% |
| 2023-Q11/2 |
LoseCTMX / S&P -5.63% / 7.50% |
WinCTMX / S&P 122.58% / 10.77% |
No dataCTMX / S&P / -15.69% |
| 2022-Q42/2 |
WinCTMX / S&P 10.34% / 7.56% |
WinCTMX / S&P 42.48% / 11.88% |
No dataCTMX / S&P / -17.99% |
| 2022-Q30/2 |
LoseCTMX / S&P -20.77% / -4.88% |
LoseCTMX / S&P -69.03% / 13.47% |
No dataCTMX / S&P / -1.41% |
| 2022-Q20/2 |
LoseCTMX / S&P -31.46% / -16.10% |
LoseCTMX / S&P -59.43% / 13.71% |
No dataCTMX / S&P / 11.04% |
| 2022-Q10/2 |
LoseCTMX / S&P -38.34% / -4.60% |
LoseCTMX / S&P -54.48% / 15.97% |
No dataCTMX / S&P / 42.23% |
| 2021-Q40/2 |
LoseCTMX / S&P -14.93% / 11.03% |
LoseCTMX / S&P -62.82% / 15.00% |
No dataCTMX / S&P / 96.40% |
| 2021-Q30/2 |
LoseCTMX / S&P -19.59% / 0.58% |
LoseCTMX / S&P -28.23% / 10.77% |
No dataCTMX / S&P / 69.42% |
| 2021-Q20/2 |
LoseCTMX / S&P -18.11% / 8.55% |
LoseCTMX / S&P -22.03% / 6.58% |
No dataCTMX / S&P / 51.81% |
| 2021-Q11/2 |
WinCTMX / S&P 18.02% / 6.17% |
LoseCTMX / S&P -13.99% / -1.06% |
No dataCTMX / S&P / 7.39% |
| 2020-Q41/2 |
LoseCTMX / S&P -1.50% / 12.15% |
WinCTMX / S&P 74.58% / -3.72% |
No dataCTMX / S&P / -33.42% |
| 2020-Q31/2 |
LoseCTMX / S&P -20.17% / 8.93% |
WinCTMX / S&P 52.05% / -2.04% |
No dataCTMX / S&P / -27.10% |
| 2020-Q21/2 |
LoseCTMX / S&P 8.60% / 20.54% |
WinCTMX / S&P 36.36% / -0.46% |
No dataCTMX / S&P / -27.11% |
| 2020-Q12/2 |
WinCTMX / S&P -7.70% / -19.60% |
WinCTMX / S&P 3.74% / 3.47% |
No dataCTMX / S&P / -14.75% |
| 2019-Q41/2 |
WinCTMX / S&P 12.60% / 9.07% |
LoseCTMX / S&P -3.38% / 5.36% |
No dataCTMX / S&P / 2.99% |
| 2019-Q30/2 |
LoseCTMX / S&P -34.22% / 1.70% |
LoseCTMX / S&P -19.20% / 5.02% |
No dataCTMX / S&P / 0.21% |
| 2019-Q21/2 |
WinCTMX / S&P 4.37% / 4.30% |
LoseCTMX / S&P -27.97% / 6.64% |
No dataCTMX / S&P / 8.65% |
| 2019-Q10/2 |
LoseCTMX / S&P -28.81% / 13.65% |
LoseCTMX / S&P 0.88% / 8.12% |
No dataCTMX / S&P / 14.29% |
| 2018-Q40/2 |
LoseCTMX / S&P -18.38% / -13.52% |
LoseCTMX / S&P -16.92% / 9.05% |
No dataCTMX / S&P / 18.23% |
| 2018-Q31/2 |
LoseCTMX / S&P -19.07% / 7.71% |
WinCTMX / S&P 54.46% / 10.21% |
No dataCTMX / S&P / 19.06% |
| 2018-Q21/2 |
LoseCTMX / S&P -19.65% / 3.43% |
WinCTMX / S&P 210.53% / 9.03% |
No dataCTMX / S&P / 14.46% |
| 2018-Q12/2 |
WinCTMX / S&P 34.77% / -0.76% |
WinCTMX / S&P 232.90% / 7.68% |
No dataCTMX / S&P / 12.46% |
| 2017-Q42/2 |
WinCTMX / S&P 16.18% / 6.64% |
WinCTMX / S&P 457.59% / 7.03% |
No dataCTMX / S&P / 13.82% |
| 2017-Q32/2 |
WinCTMX / S&P 17.23% / 4.48% |
WinCTMX / S&P 351.93% / 5.68% |
No dataCTMX / S&P / 17.57% |
| 2017-Q21/2 |
LoseCTMX / S&P -10.25% / 3.09% |
WinCTMX / S&P 202.17% / 4.83% |
No dataCTMX / S&P / 17.74% |
| 2017-Q12/2 |
WinCTMX / S&P 57.14% / 6.07% |
WinCTMX / S&P 171.88% / 3.67% |
No dataCTMX / S&P / 13.32% |
| 2016-Q41/2 |
LoseCTMX / S&P -29.91% / 3.82% |
WinCTMX / S&P 66.56% / 2.09% |
No dataCTMX / S&P / 7.05% |
| 2016-Q32/2 |
WinCTMX / S&P 53.50% / 3.85% |
WinCTMX / S&P 41.85% / 0.20% |
No dataCTMX / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CTMX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 67.65% | 20.78% |
| Annualized return | 67.65% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CTMX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -34.23% | 83.14% |
| Annualized return | -8.04% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | CTMX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -70.82% | 319.30% |
| Annualized return | -11.59% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |